|
24 Jun 2021 |
Antios Therapeutics’ ATI-2173 Demonstrates Potent Antiviral Activity and Evidence of Off-Treatment Sustained Viral Suppression in Chronic HBV Patients
|
|
24 Jun 2021 |
Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven
|
|
24 Jun 2021 |
Seal Rock Therapeutics Announces Initiation of Phase 1 Clinical Trial of ASK1 Inhibitor SRT-015 for NASH
|
|
24 Jun 2021 |
First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combination Study of Talazoparib and Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
|
|
24 Jun 2021 |
Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs
|
|
23 Jun 2021 |
Seven and Eight Biopharmaceuticals Inc. Announces the First Patient Treated in a First-in-Human Clinical Trial of the TLR7/8 dual agonist BDB018 in Advanced Solid Tumors
|
|
23 Jun 2021 |
Orum Therapeutics Closes $84 Million Series B Financing to Advance Novel Targeted Protein Degrader Payloads into Clinical Trials for Cancer
|
|
23 Jun 2021 |
Enanta Pharmaceuticals Reports Positive Data from Phase 1b Study of EDP-514, a Hepatitis B Virus (HBV) Core Inhibitor, in Viremic Chronic HBV Patients
|
|
22 Jun 2021 |
Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
|
|
22 Jun 2021 |
Kymera Therapeutics Presents New Preclinical Data for its IRAKIMiD Degrader KT-413 Demonstrating Strong Antitumor Activity as Both Monotherapy and in Combination in MYD88-mutant Lymphoma Models
|
|
22 Jun 2021 |
C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the 16th Annual International Conference on Malignant Lymphoma
|
|
22 Jun 2021 |
Preliminary Results From RELIANT Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
|
|
22 Jun 2021 |
Galecto’s GB0139 Shows Favorable Safety and Tolerability Profile with Promising Changes in Efficacy Markers in Hospitalized COVID-19 Patients
|
|
22 Jun 2021 |
Jardiance® (empagliflozin) approved in Europe for the treatment of heart failure with reduced ejection fraction
|
|
22 Jun 2021 |
Imbria Pharmaceuticals Announces Enrolment of the First 10 Patients in IMPROVE-DiCE, an Exploratory Phase 2 Study Investigating the impact of IMB-1018972 on Cardiac Energetics, Metabolism and Function in Patients with Type 2 Diabetes
|
|
22 Jun 2021 |
Moleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases
|
|
22 Jun 2021 |
Koselugo approved in the EU for children with neurofibromatosis type 1 and plexiform neurofibromas
|
|
22 Jun 2021 |
Bayer submits regulatory applications for oncology treatment combination of copanlisib and rituximab in the U.S. and EU
|
|
20 Jun 2021 |
First Patient Dosed in Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion
|
|
20 Jun 2021 |
European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis
|
|
20 Jun 2021 |
Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering US$20 Million Milestone Payment
|
|
19 Jun 2021 |
Bristol Myers Squibb Receives European Commission Approval for Onureg® (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia
|
|
17 Jun 2021 |
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214
|
|
17 Jun 2021 |
Anji to Advance MCL1 Inhibitor Program from Broad Institute into Clinical Trials
|
|
17 Jun 2021 |
Qpex Biopharma Initiates Phase 1 Study of QPX9003 Targeting Antibiotic-Resistant Pathogens
|
